Relay Therapeutics Announces Initial Clinical Data Demonstrating That Zovegalisib Has Potential for Differentiated Safety and Efficacy in Patients with PIK3CA-Driven Vascular Anomalies
Go back to Relay Therapeutics Announces Initial Clinical Data Demonstrating That Zovegalisib Has Potential for Differentiated Safety and Efficacy in Patients with PIK3CA-Driven Vascular Anomalies| (NASDAQ: RLAY) | Delayed: 17.44 +0.16 (0.93%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $17.28 | 52 Week High | $ | |||
| Open | $16.65 | 52 Week Low | $ | |||
| Day High | $17.70 | P/E | N/A | |||
| Day Low | $16.65 | EPS | $ | |||
| Volume | 5,388,490 | |||||
